Isoform-specific knockdowns may help answer whether different MSI-2 isoforms have diverging effects on breast cancer cells, as suggested by Li et al. Additionally, future work in primary cell cultures, tumor organoids or in vivo work may help solve this contradiction. This evidence concerns the gene MSI2 and breast carcinoma.